A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

NCT06642584 · Completed

Last updated 2026-05-28

This study is testing a new protein-based tablet containing semaglutide in healthy men to see how the body absorbs it.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 90 people

Who can join Ages 18–64 · male only Healthy volunteers accepted.

Timeline Started 2024-10 · est. completion 2025-08

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT06642584 ↗

Description as written by the study sponsor.

This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.

Treatments tested

Semaglutide B Drug

Semaglutide B will be administered subcutaneously.
Semaglutide J Drug

Semaglutide J will be administered as oral tablets.
Semaglutide L Drug

Semaglutide L will be administered as oral tablets.
Semaglutide M Drug

Semaglutide M will be administered as oral tablets.
Semaglutide N Drug

Semaglutide N will be administered as oral tablets.

Main thing measured	Adjusted AUC(sema); adjusted area under the semaglutide plasma concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Healthy Volunteers Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06642584 ↗